Edition:
United States

Heron Therapeutics Inc (HRTX.OQ)

HRTX.OQ on NASDAQ Stock Exchange Capital Market

23.80USD
16 Feb 2018
Change (% chg)

$-0.10 (-0.42%)
Prev Close
$23.90
Open
$23.80
Day's High
$24.40
Day's Low
$23.60
Volume
130,765
Avg. Vol
207,959
52-wk High
$24.75
52-wk Low
$12.70

Chart for

About

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery... (more)

Overall

Beta: 1.71
Market Cap(Mil.): $1,297.21
Shares Outstanding(Mil.): 54.50
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Heron Therapeutics Announces Pricing Of Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Dec 05 2017

BRIEF-Heron Therapeutics Announces Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

Dec 04 2017

BUZZ-Heron Therapeutics: FDA approves chemotherapy-induced nausea drug

** Drug developer's shares rise 4.9 pct to $18.20 after market

Nov 09 2017

BRIEF-Heron Therapeutics gets FDA approval for Cinvanti

* Announces U.S. FDA approval of Cinvanti™ (aprepitant) injectable emulsion for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (cinv)

Nov 09 2017

BRIEF-Heron Therapeutics reports qtrly diluted net loss per share $0.77

* Heron Therapeutics reports financial results for the three and nine months ended September 30, 2017 and recent corporate progress

Nov 06 2017

BRIEF-Heron Therapeutics granted FDA fast track designation for HTX-011

* Heron Therapeutics granted FDA fast track designation for HTX-011 to reduce postoperative pain and the need for opioid analgesics for 72 hours

Oct 26 2017

Competitors

Earnings vs. Estimates